T2-weighted, apparent diffusion coefficient and 18F-FDG PET histogram analysis of rectal cancer after preoperative chemoradiotherapy

Tech Coloproctol. 2021 May;25(5):569-577. doi: 10.1007/s10151-021-02440-9. Epub 2021 Apr 1.

Abstract

Background: The aim of our study was to investigate the correlation among T2-weighted (T2w) images, apparent diffusion coefficient (ADC) maps, 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) images, histogram analysis and the pathological response in locally advanced rectal cancer (LARC) after preoperative chemoradiotherapy (pCRT).

Methods: Patients with LARC were prospectively enrolled between February 2015 and August 2018 and underwent PET/magnetic resonance imaging (MRI). MRI included T2w and diffusion-weighted imaging (DWI)-sequences. ADC maps and PET images were matched to the T2w images. Voxel-based standardized uptake values (SUVs,) ADC and T2w-signal-intensity values were collected from the volumes of interest (VOIs) and mean, skewness and kurtosis were calculated. Spearman's correlation coefficient was applied to evaluate the correlation among the variables and tumor regression grade (TRG), T stage, N stage and fibrosis.

Results: Twenty-two patients with biopsy-proven LARC in the low or mid rectum were enrolled [17 males, mean age was 69 years (range 49-85 years)]. Seven patients experienced complete regression (TRG1). A significant positive correlation was found between SUV mean values (ρ = 0.480; p = 0.037) and TRG. No other significant correlations were found.

Conclusions: Histogram analysis of SUV values is a predictor of TRG in LARC.

Keywords: Magnetic resonance imaging (MRI); Positron emission tomography (PET); Preoperative chemoradiotherapy; Rectal cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy
  • Diffusion Magnetic Resonance Imaging
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Positron-Emission Tomography
  • Rectal Neoplasms* / drug therapy
  • Rectal Neoplasms* / therapy

Substances

  • Fluorodeoxyglucose F18